ViroPharma Inc. (VPHM) filed Annual Report for the period ended 2010-12-31.
Viropharma Inc. has a market cap of $1.34 billion; its shares were traded at around $17.15 with a P/E ratio of 12.4 and P/S ratio of 4.3. Hedge Fund Gurus that owns VPHM: Joel Greenblatt of Gotham Capital, Jim Simons of Renaissance Technologies LLC, Bruce Kovner of Caxton Associates, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns VPHM: Chuck Royce of Royce& Associates, Pioneer Investments, Jeremy Grantham of GMO LLC.
Highlight of Business Operations:In February 2006, we announced that we had entered into a licensing agreement with Dr. Dale Gerding, of the Hines VA, for the rights to develop a non-toxigenic strain of C. difficile (VP 20621) for the treatment and prevention of CDI. Under the license agreement, we are required to make royalty payments to Dr. Gerding based on a low single digit percentage of our net sales of the product. If certain milestones are achieved, we will be obligated to pay Dr. Gerding additional milestone payments if and when certain regulatory developments are achieved, in an aggregate amount equal to $850,000 in total, with no single milestone payment exceeding $250,000. The license agreement will remain in effect for ten years from the date any product is first commercialized, on a country-by-country basis, unless earlier terminated. The agreement contains a standard early termination provision which provides for early termination by either party in the event certain conditions have occurred, including, but not limited to, either partys breach of the agreement, either partys filing for bankruptcy or either party making an assignment for the benefit of its creditors.
In May 2010, we acquired Auralis, a UK based specialist pharmaceutical company focused on ensuring the availability and appropriate formulation of important medicinal products which address unmet medical needs for £10 million Pounds Sterling ($14.5M US dollars) in upfront consideration. ViroPharma has agreed to pay an additional payment of £10 million Pounds Sterling (approximately $15.5 million based on the December 31, 2010 exchange rate) upon the first European Medicines Agency (EMA) regulatory approval of a product in late stage development.
In October 2008, we completed our acquisition of Lev. Lev was a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The terms of the merger agreement provided for the conversion of each share of Lev common stock into upfront consideration in the aggregate amount of $453.1 million, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock, and contingent consideration (CVRs) of up to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones.
As part of the merger consideration payable to the former stockholders of Lev, we agreed to make up to two CVR payments upon the achievement of regulatory and commercial targets. Only the second CVR as described below remains achievable. The target for the first CVR payment of $0.50 per share (or $87.5 million) will not be paid as a third partys human C1 inhibitor product was approved for the acute treatment of HAE and granted orphan exclusivity. The second CVR payment of $0.50 per share ($87.5 million) becomes payable if Cinryze reaches at least $600 million in cumulative net product sales by October 2018 and we anticipate achieving this milestone in 2012.
Read the The complete Report